656 filings
6-K
IMMP
Immutep Limited
18 Apr 24
Immutep Appoints Leading Research Institute to Conduct
6:57pm
6-K
IMMP
Immutep Limited
6 Mar 24
Immutep Announces First Clinical Data from 90mg Dosing of Efti
12:00am
6-K
IMMP
Immutep Limited
29 Feb 24
Half-Year Financial Report
6:08am
SC 13G/A
FIL Ltd
9 Feb 24
IMMUTEP / FIL ownership change
7:59am
6-K
IMMP
Immutep Limited
30 Jan 24
Immutep Quarterly Activities Report & Appendix 4C
4:01pm
6-K
lii 8hs129lmyq
21 Dec 23
Immutep Receives Constructive Regulatory Feedback on TACTI-004
6:06am
6-K
gd7m7 3hew5
7 Dec 23
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
8:36pm
6-K
shxoy5vn
9 Nov 23
Current report (foreign)
5:01pm
6-K
o6rrkam
6 Nov 23
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
4:42pm
6-K
12sd6m 7kfw5ttc7igt
3 Nov 23
Immutep Announces New Biomarker Data from TACTI-002 Phase II
6:06am
6-K
uo13xo7e8 ldys
31 Oct 23
Immutep Quarterly Activities Report & Appendix 4C
6:09pm
6-K
r2ms7
25 Oct 23
Immutep receives ~A$1.13 million R&D Tax Incentive
6:07am
6-K
u14ny3ulypwwokyeeh3
24 Oct 23
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial
7:06pm
6-K
uiagubved2rrvxb 870
24 Oct 23
Current report (foreign)
6:35am
6-K
0taxgi7bi7ult
16 Oct 23
Immutep Announces Publication of Abstracts at ESMO Congress 2023
7:23pm
6-K
tnulygdn 60n
21 Sep 23
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
6:05am
6-K
55k flv7tp
2 Aug 23
Immutep Receives Positive Scientific Advice from European Medicines Agency
12:00am
6-K
hn4 sz02uxuxi
31 Jul 23
Immutep Quarterly Activities Report & Appendix 4C
9:12pm
6-K
9l0n 6gygc2
28 Jul 23
Current report (foreign)
6:31am